Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 6:55 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1897–1920 of 121,474 matching trials from the live ClinicalTrials.gov search.

Filters: Completed Clear all

Conditions: Obesity, Overweight and Obesity, Quality of Life, Health Behavior
Interventions: Noom Healthy Weight; Behavioral
Lead sponsor: Noom Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 370 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: New York, New York

Conditions: Lung Cancer, Survivor
Interventions: interview and physical activity, interview and wait list; Behavioral
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 21 Years and older
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2023
U.S. locations: 1
States / cities: New York, New York

Conditions: Primary Malignant Brain Tumors, Advanced Care Planning
Interventions: Questionnaires, Communication training Part 1 (no longer recruiting), Enhanced usual care, Communication training Part II; Other
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 49 participants
Timeline: 2019 – 2024
U.S. locations: 1
States / cities: New York, New York

Conditions: Age-related Macular Degeneration
Interventions: Subcutaneous elamipretide through the elamipretide delivery system, Subcutaneos placebo through the elamipretide delivery system; Combination Product
Lead sponsor: Stealth BioTherapeutics Inc.; Industry
Eligibility: 55 Years and older
Enrollment: 176 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 37
States / cities: Peoria, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 30 more

Conditions: Scleritis
Interventions: Infliximab; Drug
Lead sponsor: National Eye Institute (NEI); NIH
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2007
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Osteoarthritis
Interventions: Methylprednisolone and Lidocaine, Placebo and Lidocaine; Drug
Lead sponsor: University of Kansas Medical Center; Other
Eligibility: 40 Years to 85 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Kansas City, Kansas

Conditions: Dry Eye Disease (DED)
Interventions: NOV03, Placebo; Drug
Lead sponsor: Novaliq GmbH; Industry
Eligibility: 18 Years and older
Enrollment: 336 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 11
States / cities: Artesia, California • Newport Beach, California • Santa Ana, California + 6 more

Conditions: CNS Lesion, Blood Brain Barrier Defect
Interventions: P03277, Gadobenate dimeglumine, MRI; Drug · Device
Lead sponsor: Guerbet; Industry
Eligibility: 18 Years and older
Enrollment: 312 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 10
States / cities: Chicago, Illinois • Boston, Massachusetts • Farmington Hills, Michigan + 6 more

Conditions: Osteoarthritis, Knee, Knee Replacement
Interventions: Mindfulness-based Cognitive Behavioral Therapy; Behavioral
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 45 Years to 100 Years
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 1
States / cities: Chestnut Hill, Massachusetts

Conditions: Non-Hodgkin Lymphoma, Hodgkin Disease
Interventions: G-CSF plus plerixafor, rituximab; Drug · Biological
Lead sponsor: Genzyme, a Sanofi Company; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Hand Foot Skin Reaction
Interventions: Sildenafil; Drug
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 2
States / cities: Chicago, Illinois

Conditions: Diabetes, Diabetes Mellitus, Type 2
Interventions: semaglutide, placebo; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 397 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 72
States / cities: Phoenix, Arizona • Anaheim, California • Fresno, California + 63 more

Conditions: Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia
Interventions: DCDT2980S, rituximab; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 91 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 9
States / cities: Stanford, California • Denver, Colorado • Washington D.C., District of Columbia + 5 more

Conditions: Proliferative Vitreoretinopathy
Interventions: Isotretinoin; Drug
Lead sponsor: Wills Eye; Other
Eligibility: 18 Years to 80 Years
Enrollment: 109 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Alzheimer's Disease
Interventions: Placebo, octagam 10%; Drug · Biological
Lead sponsor: Octapharma; Industry
Eligibility: 50 Years to 85 Years
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Hoboken, New Jersey

Conditions: Unemployment
Interventions: Purposeful Pathways, Transitional Work Experience; Behavioral
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years and older
Enrollment: 67 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Bedford, Massachusetts

Conditions: Maternal Depression
Interventions: Problem Solving Education; Behavioral
Lead sponsor: Boston Medical Center; Other
Eligibility: 15 Years and older · Female only
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Breast Cancer, Arthralgia
Interventions: Exercise, Attention Control (Health Education); Behavioral
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 75 Years · Female only
Enrollment: 121 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Healthy Participants
Interventions: TAK-994; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 54 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 2
States / cities: Tempe, Arizona • Lincoln, Nebraska

Conditions: Prostate Cancer, Breast Cancer Female
Interventions: Exercise; Behavioral
Lead sponsor: Celina Shirazipour; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Non-Hodgkin, Lymphoma, T-Cell
Interventions: brentuximab vedotin, rituximab; Drug
Lead sponsor: Seagen Inc.; Industry
Eligibility: 6 Years and older
Enrollment: 176 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 33
States / cities: Birmingham, Alabama • Duarte, California • Oxnard, California + 26 more

Conditions: Multiple Myeloma and Plasma Cell Neoplasm
Interventions: filgrastim, dexamethasone, melphalan, thalidomide; Biological · Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2002
U.S. locations: 1
States / cities: New York, New York

Conditions: Alzheimer's Disease
Interventions: icosapent ethyl (IPE), gel cap placebo; Drug · Other
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 50 Years to 75 Years
Enrollment: 131 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2023
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Anemia
Interventions: Roxadustat, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 2,781 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 97
States / cities: Birmingham, Alabama • Huntsville, Alabama • Phoenix, Arizona + 72 more

Search by objective public record fields.

Improving Quality of Life in Men and Women With Overweight or Obesity

Physical Activity Intervention for Lung Cancer Survivors

Communication Training for Caregivers In Advanced Care Planning

ReCLAIM-2 Study to Evaluate Safety,Efficacy & Pharmacokinetics of Elamipretide in Subjects With AMD With Non-central GA

Infliximab to Treat Non-Infectious Scleritis

Effect of Intraarticular Steroids on Bone Turnover in Osteoarthritis

Perfluorohexyloctane (NOV03) for the Treatment of Signs and Symptoms of Dry Eye Disease (DED)

P03277 Dose Finding Study in Central Nervous System (CNS) Magnetic Resonance Imaging (MRI)

Prediction of Outcomes Following Total Knee Replacement- Pilot

The Effect of Rituximab on Mobilization With AMD3100 (Plerixafor) Plus G-CSF in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma (NHL) or Hodgkin Disease (HD)

Topical Sildenafil as Pre-Treatment for Hand-Foot Skin Reaction

Efficacy and Safety of Semaglutide Once-weekly Versus Placebo as add-on to Basal Insulin Alone or Basal Insulin in Combination With Metformin in Subjects With Type 2 Diabetes

A Study of the Safety and Pharmacokinetics of Escalating Doses of DCDT2980S in Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia And DCDT2980S in Combination With Rituximab in Patients With Relapsed or Refractory B-Cell Non Hodgkin's Lymphoma

Isotretinoin for Proliferative Vitreoretinopathy

Study of Octagam (Intravenous Immunoglobulin [IVIG]) 10% on the Treatment of Mild to Moderate Alzheimer's Disease

Improving Vocational Outcomes of Veterans With Psychiatric Disorders: Career Counseling & Development

Problem Solving Education and Neonatal Intensive Care Unit (NICU) Mothers

Hormones and Physical Exercise (HOPE) Study

A Study of Different Forms of TAK-994 in Healthy Adults

Streaming Web-based Exercise At Home: A Pilot Study

A Study of Brentuximab Vedotin in Relapsed or Refractory Non-Hodgkin Lymphoma

Melphalan, Thalidomide, and Dexamethasone in Treating Patients With Newly Diagnosed, Previously Untreated Primary Systemic Amyloidosis

Brain Amyloid and Vascular Effects of Eicosapentaenoic Acid

Safety and Efficacy Study of Roxadustat to Treat Anemia in Patients With Chronic Kidney Disease (CKD), Not on Dialysis